Credit is awarded in the calendar year the assessment is completed. AAPP reports continuing credit for ACPE (CPE Monitor) and BCPP Recertification (BPS) within days of successful exam completion.
Target Audience
BCPPs desiring an evidence-based, in-depth review of contemporary issues in psychiatric pharmacy at the specialist level are the intended audience of this recertification activity. This activity is designed for BCPPs who are auditory and visual learners and/or who learn best from hands-on-learning and dialoguing with specialist faculty and colleagues.
Course Requirements
To satisfactorily complete the recertification programming and receive BCPP Recertification and ACPE credit, candidates must meet the following requirements:
- Register for this course.
- Complete the pre-test before starting the activity.
- Review the full content of the activity and reflect upon its teachings.
- Abide by a confidentiality and honesty statement requiring individual completion of the course.
- Complete the post-test at the end of the activity no later than the closing activity date.
- Complete an activity evaluation form.
- Wait for an official review of exam questions within 4 weeks following the closing date.
- Receive a passing grade (72%).
- Partial credit is not provided; your exam score must meet or exceed the cut-off score in order to receive the ACPE and BCP Recertification credit.
- Learners who do not achieve a passing score on a post-activity assessment may appeal assessment questions and/or take a remediation assessment. View AAPP's Post-Activity Assessment Appeal and Remediation Policy.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Faculty Information
View biographical information
Michelle Geier, PharmD, BCPP, APh
Psychiatric Clinical Pharmacist
San Francisco Department of Public Health
San Francisco, CA
Michelle Geier is a psychiatric clinical pharmacist for San Francisco Department of Public Health (SFDPH). She is currently deployed as a disaster service worker for SFDPH as the Substance Use Services Pharmacy Lead to address the local opioid overdose crisis. In her usual roll, she manages a caseload of psychiatric and substance use disorders clients under a collaborative practice agreement at a county mental health clinic that predominantly serves people experiencing homelessness on admission and dual diagnosis. She oversees substance use disorder clinical services at our county mental health and substance use disorders pharmacy that serves approximately 1200 people with opioid use disorder annually. She participates in multiple quality improvement committees for the health plan that is responsible for all Medicaid beneficiaries with a serious mental illness in San Francisco county. I serve as the Residency Program Director for our PGY2 in psychiatry.
Robert Hudak, MD
Professor of Psychiatry, University of Pittsburgh School of Medicine
Medical Director, Center for Obsessive Compulsive and related Disorders, University of Pittsburgh Medical Center
University of Pittsburgh School of Medicine
Pittsburgh, PA
Robert Hudak, MD is a Professor of Psychiatry at the University of Pittsburgh School of Medicine. He is currently the medical director of the Center for Treatment of Obsessive-Compulsive and Anxiety Disorders at Western Psychiatric Hospital. He serves on the IOCDF Scientific and Clinical Advisory Board. He has authored numerous articles and book chapters on OCD and is a co-author of ‘Handbook of Psychiatric Disorders in Adults in the Primary Care Setting” and is the co-chair of the Autism in OCD SIG for the IOCDF. He lectures on OCD in numerous settings both nationally and internationally.
Kayla Johnson, PharmD, BCPS, BCPP
Clinical Pharmacist Specialist
Vanderbilt University Medical Center
Nashville, TN
David Parra, PharmD, BCPS, FCCP, FAHA
VISN 8 PBM Clinical Pharmacy Program Manager in Cardiology & Anticoagulation
Veterans Health Administration
Damian Peterson, PharmD, BCPP, BCPS, APh
Psychiatric Clinical Pharmacist
San Francisco Department of Public Health
San Francisco, CA
Ilse Wiechers, MD, MPP, MHS
Deputy Executive Director
Veterans Health Administration Office of Mental Health
Learning Objectives
Difficult to Treat Depression – Emerging Strategies
- Describe difficult-to-treat depression (DTD) and how it can impact an individual’s treatment plan.
- Evaluate treatment options for DTD including ketamine and/or esketamine.
- Develop an evidence-based treatment plan for an individual with DTD.
Management of Tardive Dyskinesia with Vesicular Monoamine Transporter Type 2 (VMAT2) Inhibitors
- Describe the pharmacology and pharmacokinetics of VMAT2 inhibitors.
- Analyze evidence for VMAT2 inhibitors as a first-line treatment for tardive dyskinesia.
- Formulate a comprehensive treatment plan for a patient with tardive dyskinesia.
Interprofessional Care Coordination: Crossroads Between the Heart and Mind
- Provide rationale for implementation of integrated mental health and cardiology care.
- Describe the role of each member of the interprofessional care team in treating patients with comorbid depression and cardiovascular disease.
- Recommend a mental health screening and/or treatment plan for patients with depression and comorbid cardiovascular disease.
Out With the Old and In With the New: Removal of the X-Waiver and the Role of the Psychiatric Pharmacist
- Describe the role of psychiatric pharmacists in improving access to buprenorphine for patients with opioid use disorder.
- Apply the PRECEDE planning model to development of a psychiatric pharmacist practice managing opioid use disorder.
- Use the PROCEED model to evaluate a new psychiatric pharmacist practice managing opioid use disorder.
OCD- New and Emerging Therapies and the Role of Glutamatergic Medications
- Examine the evidence to support new and emerging therapies for obsessive compulsive disorder (OCD).
- Design a monitoring plan for individuals with OCD.
- Recommend pharmacotherapy for individuals with OCD using pharmacologic algorithms.
Download the Clinical Application Series exam to review and prepare as you navigate through each session.
Continuing Education Credit and Disclosures
Activity Dates: 04/27/2025 - 10/27/2025
ACPE Contact Hours: 5
ACPE Numbers: 0284-0000-25-003-H01-P (Application), 0284-0000-25-004-H01-P (Application), 0284-0000-25-008-H01-P (Application), 0284-0000-25-010-H04-P (Application), 0284-0000-25-012-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacists can obtain 5 hours of ACPE credit and 5 hours of BCPP Recertification credit by successfully completing the online Clinical Application Series examination.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View planning committee disclosures
2025 Recertification Editorial Board
| Marissa Cullen, PharmD, BCPP Clinical Pharmacist UPMC Western Psychiatric Hospital Pittsburgh, PA No Relevant Financial Relationships to Disclose |
| Beth DeJongh, PharmD, BCPS, BCPP Director of Continuing Professional Development American Association of Psychiatric Pharmacists Lincoln, NE No Relevant Financial Relationships to Disclose |
| Traci Dutton, PharmD, BCPP, BCPS Clinical Pharmacy Specialist - Mental Health; Program Director - PGY2 Psychiatry VA Tennessee Valley Healthcare System Murfreesboro, TN No Relevant Financial Relationships to Disclose |
| Megan Ehret, PharmD, MS, BCPP Professor Monrovia, MD External Consultant Activities, Advisory Panels, Speakers Bureaus, etc.: Saladex Biomedical Consultant, Lexi-Comp Consultant/Reviewer, SMI Adviser; Pharmacist Consultant Educational Grants, Research Grants or Contracts: FDA/University of Maryland CERSI, Maryland Behavioral Health Department, NIH |
| Jordan Haygood, PharmD, BCPP Clinical Pharmacy Specialist - Psychiatry Medical University of South Carolina (MUSC) College of Pharmacy No Relevant Financial Relationships to Disclose |
| Courtney Iuppa, PharmD, BCPP Clinical Pharmacy Manager & Residency Program Director Center for Behavioral Medicine Kansas City, MO No Relevant Financial Relationships to Disclose |
| Archana Jhawar, PharmD, BCPP Clinical Pharmacist University of Illinois at Chicago College of Pharmacy Chicago, IL No Relevant Financial Relationships to Disclose |
| Linda Logan, PharmD, BCACP, BCPP, BCPS Public Service Associate University of Georgia College of Pharmacy Athens, GA Educational Grants, Research Grants or Contracts: HRSA Graduate Psychology Education Grant, UGA Mental Health Seed Grants for MHFA and Virtual Dementia Tour, UGA College Pharmacy Ansel Fund |
| Jessica Mulhollan, PharmD, BCPP Clinical Pharmacist Practitioner, Substance Use Disorders Northeast Ohio VA Healthcare System Cleveland, OH No Relevant Financial Relationships to Disclose |
| Melissa Palmer, PharmD, BCPP, BCPS Clinical Pharmacy Specialist - Mental Health Alaska VA Healthcare System Anchorage, AK No Relevant Financial Relationships to Disclose |
| Jake Peters, PharmD, BCPP, BCPS Assistant Professor of Pharmacy Practice/Clinical Pharmacy Specialist - Psychiatry Butler University College of Pharmacy and Health Sciences No Relevant Financial Relationships to Disclose |
| Sarah Popish, PharmD, BCPP VA PBM Academic Detailing Services, Program Manager Department of Veterans Affairs No Relevant Financial Relationships to Disclose |
| Alisha Striedel, PharmD, BCPP Mental Health Clinical Pharmacist Practitioner Central Texas Veterans Health Care System Temple, TN No Relevant Financial Relationships to Disclose |
| Kara Wong, PharmD, BCPP Clinical Pharmacist Practitioner, Mental Health Minneapolis VA Health Care System Minneapolis, MN No Relevant Financial Relationships to Disclose |
All relevant relationships have been mitigated.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.
In accordance with the Food and Drug Administration (FDA), it is disclosed that there is the potential for discussions concerning off-label uses of a commercial product/devices during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose significant relationships (and any known relationships of their spouse/partner) with commercial companies whose products or services are discussed in this activity. Significant relationships include receiving from a commercial company research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.